Pfizer's SHP2 Inhibitor PF-07284892 Receives IND Approval in China for Advanced Solid Tumors

Intelligent Finance APP learned on February 22 that the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration disclosed that PF-07284892 tablets, submitted by Pfizer (PFE.US), had obtained tacit approval for clinical trials. The drug is proposed to be developed for the treatment of advanced solid tumors. Public information shows that PF-07284892 is an SHP2 inhibitor in Pfizer's R&D pipeline and is a new molecular entity. Phase 1 clinical research for the treatment of advanced solid tumors is currently underway overseas.

SHP2, fully known as the Src Homology Region 2 Domain-Containing Phosphatase, is a key signaling node and regulator that promotes cancer cell survival and growth through the RAS pathway. It plays a crucial role in how cancer cells develop resistance to targeted therapies. For decades, it has been considered an "undruggable" target. However, with recent advancements in research, the development of SHP2-targeted drugs has gradually made breakthroughs, making it one of the leading targets in current new drug development. It also holds the potential to be combined with various drugs, including immune checkpoint inhibitors, to enhance the effectiveness of cancer treatment.

PF-07284892 tablets are an SHP2 inhibitor in Pfizer's oncology drug pipeline. According to the ClinicalTrials website, this product is currently undergoing a first-in-human Phase 1 clinical trial in patients with advanced solid tumors. The aim of the study is to determine the maximum tolerated dose of the product, while also investigating its pharmacokinetics, safety, and preliminary clinical activity both as a single agent and in combination therapies with ALK inhibitors, BRAF inhibitors, MEK inhibitors, anti-EGFR antibodies, and other drugs.